



AAVBC

AMERICAN ACADEMY OF VALUE BASED CARE

Acute Leukemia

Quick Reference Guide

2026

Table of Contents

1. CLINICAL SNAPSHOT	3
HCC/RAF V28 Mapping	3
2. RECOGNITION AND DIAGNOSIS	6
Diagnostic Workup Covered Under Medicare Part B (older adults, at-risk population)	6
Subtle Early Signs in Older Adults	6
Risk Factors	7
Diagnostic Thresholds	8
Key Distinguishing Features Between Acute and Chronic Leukemias	8
Common Oversights	10
Key Differentials in Elderly	11
Comorbidity Screening	12
Staging and Risk Stratification Systems for AML and ALL	13
3. MEAT DOCUMENTATION ESSENTIALS	18
Reframing Common Documentation Shortcuts	19
4. TREATMENT AND REFERRAL QUICK GUIDE	19
Therapy Escalation Criteria	20
NCCN/ASH 2025 Aligned Recommendations	20
Non-Pharmacologic Treatment and Lifestyle Modification	21
Non-Pharmaceutical Prevention Strategies	22
Medication Safety Considerations	22
When to Refer	23
Follow-Up Timing	24
Comorbidity Management	24
Cost-Smart Options	25
Patient Education and Adherence	26
Quality Metrics Tie-In	27
5. CODING REMINDERS AND CASE EXAMPLES	29
Documentation Specificity	29
Annual Clinical Review and Confirmation	30
Good Documentation is Comprehensive Coding	30
EHR Workflow Tips	31
Brief Case Examples	31
REFERENCES	32

1 CLINICAL SNAPSHOT

Definition: Acute leukemias are a group of rapidly progressing **hematologic malignancies** characterized by uncontrolled clonal proliferation of immature blood cells (blasts) in the bone marrow, resulting in profound cytopenias and **failure of normal hematopoiesis**. The two principal adult subtypes are acute myeloid leukemia (**AML**) and acute lymphoblastic leukemia (**ALL**).

ICD-10 Codes

AML (HCC 17): C92.0x (AML, not elsewhere classified), C92.3x (myeloid sarcoma), C92.5x (acute myelomonocytic leukemia), C92.6x (acute myeloid leukemia with 11q23-abnormality), C92.Ax (acute myeloid leukemia with multilineage dysplasia), C93.0x (acute monoblastic/monocytic leukemia), C94.0x (acute erythroid leukemia), C94.2x (acute megakaryoblastic leukemia), C94.4x (acute panmyelosis with myelofibrosis), C92.4x (acute promyelocytic leukemia). **ALL (HCC 18):** C91.0x (acute lymphoblastic leukemia). **Unspecified Acute Leukemia (HCC 18):** C95.0x (acute leukemia of unspecified cell type = **AVOID** when subtype is known).

For all acute leukemia ICD-10 codes, a **6th character is required**, and omitting this character produces an unspecified code that may map to a **lower-weighted HCC: 0** = not in remission, **1** = in remission, **2** = in relapse. **Example: C94.00** acute erythroid leukemia, not having achieved remission.

Prevalence: ~22,010 new **AML** diagnoses/year¹ and ~6,500 new **ALL** diagnoses/year in the U.S.² Median age at AML diagnosis **68-69 years**;¹ annual AML incidence reaches 17.3 per 100,000 in adults ≥70 and 5-year overall survival is ~62% in patients <50 but **falls to ~9.4%** in those ≥65;³ 5-year OS for adult ALL >60 is **<20-30%**;⁴ **Inpatient utilization** dominates acute leukemia costs in both AML and ALL. For AML, monthly per-patient costs nearly double post-relapse (~\$23,000 in remission vs. ~\$38,000 after relapse), with first salvage therapy reaching **~\$172,000/month**.^{5,6} For ALL, relapsed adults spend over half of follow-up time hospitalized, with relapse-related admissions averaging **\$132,000**; pre-transplant cancer-related costs in ALL (**\$462,000**) exceed all other hematologic malignancies.^{7,8} These data underscore that delayed detection and relapsed disease disproportionately amplify hospital-driven expenditures across both subtypes.

HCC/RAF V28 Mapping

ICD-10 CODE(S) ⁹	HCC CATEGORY (V28) ¹⁰	RAF WEIGHT (CNA) ¹¹	DOCUMENTATION REQUIREMENT ⁹
C92.0(0/1/2) (AML) C92.3(0/1/2) C92.5(0/1/2) C92.6(0/1/2) C92.A(0/1/2) C93.0(0/1/2)	HCC 17 Cancer Metastatic to Lung/Liver/Brain; AML Except Promyelocytic	4.209	Specify AML subtype per pathology; document remission status (0/1/2) at each encounter; confirm active disease annually via MEAT; do not use Z85.6 while on any active therapy

ICD-10 CODE(S) ⁹	HCC CATEGORY (V28) ¹⁰	RAF WEIGHT (CNA) ¹¹	DOCUMENTATION REQUIREMENT ⁹
C94.00 (acute erythroid leukemia) C94.20 (acute megakaryoblastic) C94.40 (acute panmyelosis w/ myelofibrosis)	HCC 18 Cancer Metastatic to Bone/Other and Unspecified Metastatic Cancer; Acute Leukemia Except Myeloid	2.341	Rare subtypes = confirm lineage with hematopathology; document remission status (0/1/2) at each encounter; specify morphologic subtype per WHO/ICC classification
C91.0(0/1/2) (ALL)	HCC 18 Cancer Metastatic to Bone/Other and Unspecified Metastatic Cancer; Acute Leukemia Except Myeloid	2.341	Specify ALL (not "acute leukemia"); document remission status (0/1/2) at each encounter; ALL maintenance spans 2.5–3 yr: code as active disease throughout, not Z85.6
C95.0(0/1/2) (acute leukemia, unspecified cell type)	HCC 18 Cancer Metastatic to Bone/Other and Unspecified Metastatic Cancer; Acute Leukemia Except Myeloid	2.341	AVOID once AML vs. ALL is pathologically confirmed; replace with lineage-specific code (C92.0x or C91.0x); unspecified coding forecloses HCC 17 mapping for AML
C92.4(0/1/2) (Acute Promyelocytic Leukemia; APL)	HCC 18 Cancer Metastatic to Bone/Other and Unspecified Metastatic Cancer; Acute Leukemia Except Myeloid	2.341	Distinct, curable AML subtype; document PML::RARA confirmation; note remission status (0/1/2) at each encounter
Z85.6 (personal history of leukemia)	No HCC	–	Use ONLY after all treatment is completed AND no active therapy of any kind (including maintenance chemotherapy, palliative transfusions, or oncology surveillance monitoring)

ABBREVIATIONS: ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; APL = acute promyelocytic leukemia; CMS = Centers for Medicare & Medicaid Services; CNA = Community Non-Dual Eligible, Aged; HCC = Hierarchical Condition Category; MEAT = Monitor/Evaluate/Assess/Treat; RAF = Risk Adjustment Factor

RAF values represent the Community Non-Dual Eligible Aged (CNA) coefficient from the 2026 CMS-HCC model; values vary across patient populations based on eligibility and care setting

Risk-Adjusted Care Resources per Patient/Year^{3,4}

Risk-adjusted care resource allocation — MA base rate (~\$10,402.34) × RAF coefficient

AML
~\$43.8K+

HCC 17 · RAF 4.209 + chemo costs

ALL
~\$24.4K+

HCC 18 · RAF 2.341 + chemo costs

RAF values represent the Community Non-Dual Eligible Aged (CNA) coefficient from the 2026 CMS-HCC model; values vary across patient populations based on eligibility and care setting

**AAVBC PERSPECTIVE**

*From the AAVBC's perspective, value-based care in acute leukemia should focus on optimizing survival, reducing relapse risk, preserving functional independence, and improving quality of life through **clinically individualized care** rather than rigid, one-size-fits-all treatment pathways. In both AML and ALL, this includes **frailty-guided therapy intensity**, early integration of **palliative care** for symptom management and supportive services, assessment of **medication affordability** and access barriers, and development of **closed-loop care pathways** linking hematology specialists, PCPs, infusion services, transfusion support, and home or outpatient monitoring programs. The hematology community is increasingly shifting toward integrated delivery models and **outpatient-based management** for appropriate phases of disease to reduce avoidable hospitalizations, treatment toxicity, and fragmentation of care while maintaining clinical outcomes. **AAVBC emphasizes** that treatment decisions in older or medically complex patients should incorporate functional status, comorbidities, caregiver support, polypharmacy, and patient goals alongside disease biology to deliver care that is both evidence-based and patient-centered.*

2 RECOGNITION AND DIAGNOSIS

Diagnostic Workup Covered Under Medicare Part B (older adults, at-risk population)

TEST	FREQUENCY	CPT CODE	CLINICAL INDICATION ¹²⁻¹⁵
CBC with differential	As clinically indicated; at any unexplained symptom	85025	Unexplained fatigue, recurrent infection, bleeding, bruising, cytopenias, or WBC >50,000/μL with abnormal differential
Peripheral blood smear review	When CBC abnormal or blasts suspected*	85060	Confirm presence of blasts, atypical lymphocytes, or dysplastic features on automated CBC flag
Comprehensive metabolic panel (CMP)	At diagnosis and during active therapy	80053	Baseline renal/hepatic function; TLS monitoring (K ⁺ , uric acid, phosphate, calcium)
LDH and uric acid	At diagnosis and pre-therapy	83615/ 84550	Tumor burden assessment; TLS risk stratification

ABBREVIATIONS: CBC = complete blood count; CMP = comprehensive metabolic panel; CPT = current procedural terminology; LDH = lactate dehydrogenase; TLS = tumor lysis syndrome; WBC = white blood cell

***Test covered under Medicare Part B when flagged by CBC test results**

Subtle Early Signs in Older Adults

SIGN/SYMPTOM ¹²⁻¹⁵	CLINICAL SIGNIFICANCE ^{3,12-15}
Unexplained fatigue, pallor, exertional dyspnea	Anemia from marrow replacement by blasts; often misattributed to age or cardiac disease in older adults
Easy bruising, petechiae, gum/nasal bleeding	Thrombocytopenia; petechiae on lower extremities or palate are early tell-tale signs
Recurrent or severe infection, persistent fever $\geq 38.0^{\circ}\text{C}$	Functional neutropenia despite normal or elevated WBC count; any fever warrants same-day workup ¹⁶

SIGN/SYMPTOM ¹²⁻¹⁵	CLINICAL SIGNIFICANCE ^{3,12-15}
Bone or joint pain, especially sternal tenderness	Marrow expansion from blast infiltration; classic but underreported in geriatric presentations
Night sweats, unintentional weight loss	Systemic disease burden; often confused with occult infection or other malignancy
Hepatosplenomegaly or painless lymphadenopathy (ALL)	Extramedullary disease; more common in ALL than AML ¹⁷
ABBREVIATIONS: WBC = white blood cell count; ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia	

Risk Factors

FACTOR ^{14,15,18,19}	RISK SIGNAL	NOTES ^{14,15,18,19}
Prior MDS or MPN diagnosis	~ 30-40% of MDS cases progress to AML ²⁰	Document prior hematologic diagnosis and any prior HMA exposure = affects treatment response at AML onset
Clonal hematopoiesis of indeterminate potential (CHIP)	Prevalence ~10% in adults >65 (DNMT3A, TET2, ASXL1) ²¹	Confers 2-fold increased cardiovascular risk independent of leukemia treatment
Prior cytotoxic chemotherapy or radiation	Therapy-related AML (t-AML) risk	Document prior oncologic history; t-AML carries adverse cytogenetic profile; NCCN classifies t-AML as poor/adverse-risk ¹⁵
Benzene or petrochemical exposure (occupational)	Established environmental risk factor for AML/MDS ²²	Document occupational history at intake; relevant for disability/VA disposition
Down syndrome or inherited bone marrow failure syndrome	DS: ~ 150-fold increased AML risk before age 4; 10-20-fold increased ALL risk; IBMFS (Fanconi anemia, SDS, DBA, DC): 5-10% lifetime MDS/AML risk ^{23,24}	Document congenital condition; informs risk-adapted treatment
ABBREVIATIONS: ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; ECOG = Eastern Cooperative Oncology Group performance status; GA = geriatric assessment; HMA = hypomethylating agent; MDS = myelodysplastic syndrome; MPN = myeloproliferative neoplasm; t-AML = therapy-related AML; VA = Veterans Affairs		

Diagnostic Thresholds

TEST/MARKER ¹²⁻¹⁵	DIAGNOSIS CRITERION	NOTES
Peripheral blood blasts	Any circulating blasts on smear	Triggers same-day hematology contact; do not wait for bone marrow to initiate referral ²⁵
Bone marrow blast percentage	≥20% blasts = acute leukemia (WHO) ²⁶	AML-defining genetic abnormalities (e.g., t(8;21), inv(16), t(15;17) for APL) diagnose AML regardless of blast count ³
Cytogenetic analysis	Required at diagnosis (ASH Measure #1)	Guides ELN 2022 risk stratification (favorable/intermediate/adverse) ²⁷
Flow cytometry/immunophenotyping	Required at diagnosis	Distinguishes AML from ALL; confirms lineage for ambiguous morphology ^{2,3}
Molecular testing (FLT3, NPM1, IDH1/2, CEBPA, TP53)	Required for AML risk stratification and targeted therapy eligibility	FLT3-ITD, TP53 mutations define adverse risk; IDH1/IDH2 eligible for targeted agents

ABBREVIATIONS: ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; aPTT = activated partial thromboplastin time; APL = acute promyelocytic leukemia; ATRA = all-trans retinoic acid; DIC = disseminated intravascular coagulation; ELN = European LeukemiaNet; FLT3-ITD = FLT3 internal tandem duplication; IDH = isocitrate dehydrogenase; NPM1 = nucleophosmin 1; PT = prothrombin time; WHO = World Health Organization

Key Distinguishing Features Between Acute and Chronic Leukemias

FEATURE	AML ^{3,15,25,28}	CML ^{25,29,30}
Definition	≥20% myeloblasts (BM/PB); exceptions for AML-defining genetics	5% in chronic phase; 10-19% accelerated (AP); ≥20% blast phase (BP)
Epidemiology	Median age 68 ; incidence rises with age	Median age ~55 ; slight male predominance
Presentation	Fatigue, infection, bleeding; gingival hyperplasia (monocytic); Auer rods on smear	~50% asymptomatic ; marked leukocytosis with left shift; basophilia; massive splenomegaly
Immunophenotype	MPO+, CD13+, CD33+, CD117+; HLA-DR+ (negative in APL)	Mature granulocytic series; flow cytometry needed only in AP/BP

FEATURE	AML ^{3,15,25,28}	CML ^{25,29,30}
Genetics	FLT3, NPM1, CEBPA, t(8; ²¹), inv(16), t(15; ¹⁷) [PML::RARA]	t(9;22)(q34;q11.2) BCR::ABL1 (>95%); monitor by qPCR (IS)
Workup	BM aspirate + flow cytometry + cytogenetics + NGS molecular panel	PB or BM cytogenetics + qPCR for BCR::ABL1
	ALL ^{12-14,25}	CLL ^{25,31}
Definition	≥20% lymphoblasts (BM)	≥5×10 ⁹ /L monoclonal B lymphocytes (PB) by flow cytometry
Epidemiology	Bimodal: children ~5 y; second peak >50 y	Older adults; 70% diagnosed after age 65
Presentation	Bone/joint pain (children); lymphadenopathy; hepatosplenomegaly; CNS involvement (~5-8% adults)	~70% asymptomatic ; lymphocytosis; lymphadenopathy; modest splenomegaly
Immunophenotype	B-ALL: CD19+, CD10+, CD22+, TdT+; T-ALL: cCD3+, CD7+, TdT+	CD5+, CD19+, CD20 dim, CD23+, CD200+; kappa/lambda restriction
Genetics	BCR::ABL1 (Ph+), KMT2A-r, ETV6::RUNX1, hyperdiploidy, hypodiploidy	del(13q), +12, del(11q), del(17p); IGHV mutation status; TP53
Workup	BM aspirate + flow cytometry + karyotype + FISH/RT-PCR for BCR::ABL1 + NGS	PB flow cytometry (CD5/CD19/CD23/CD200/kappa/lambda); BM biopsy not required

ABBREVIATIONS: AML = acute myeloid leukemia; CML = chronic myeloid leukemia; BM = bone marrow; PB = peripheral blood; CP = chronic phase; AP = accelerated phase; BP = blast phase; MPO = myeloperoxidase; HLA-DR = human leukocyte antigen-DR isotype; APL = acute promyelocytic leukemia; FLT3 = fms-like tyrosine kinase 3; NPM1 = nucleophosmin 1; CEBPA = CCAAT/enhancer-binding protein alpha; PML::RARA = promyelocytic leukemia-retinoic acid receptor alpha fusion; BCR::ABL1 = breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 fusion; qPCR = quantitative polymerase chain reaction; IS = International Scale; NGS = next-generation sequencing; ALL = acute lymphoblastic leukemia; CLL = chronic lymphocytic leukemia; CNS = central nervous system; TdT = terminal deoxynucleotidyl transferase; cCD3 = cytoplasmic CD3; Ph = Philadelphia chromosome; KMT2A-r = KMT2A-rearranged; IGHV = immunoglobulin heavy chain variable region; FISH = fluorescence in situ hybridization; RT-PCR = reverse transcriptase polymerase chain reaction; TP53 = tumor protein p53

Common Oversights

OVERSIGHT/SHORTCUT	WHY IT MATTERS — WHAT TO DO INSTEAD ^{3,12-15}
Attributing fatigue, bruising, or gingival bleeding to benign causes without obtaining a CBC with differential and peripheral smear	AML can present with isolated gingival hyperplasia or mucocutaneous bleeding even with a near-normal CBC; ³² absence of blasts on smear does not exclude acute leukemia; ²⁵ any unexplained cytopenia, refractory gingival enlargement, or new petechiae warrants CBC with differential, smear review, and hematology referral
Failing to suspect APL and emergently initiate ATRA	ATRA must begin at first morphologic suspicion, before cytogenetic confirmation ; delayed ATRA (>24 h) is associated with ~3-fold increase in early hemorrhagic mortality; ³³ suspect APL when promyelocytes with multiple Auer rods, spontaneous DIC, or CD34 ⁺ /HLA-DR ⁺ immunophenotype are present
Not recognizing or urgently managing leukostasis in hyperleukocytosis	Leukostasis (dyspnea, hypoxemia, confusion, focal deficits) carries 20-40% first-week mortality; ³⁴ WBC >100×10⁹/L defines hyperleukocytosis, though monocytic AML may manifest at >50×10⁹/L ; initiate hydroxyurea immediately; avoid RBC transfusion until WBC is reduced; prompt definitive induction essential
Omitting CNS evaluation and prophylaxis in adult ALL	Without CNS-directed therapy, >50% of ALL patients develop CNS leukemia; ¹⁴ all ALL regimens must include CNS prophylaxis (systemic HD-MTX/cytarabine + IT therapy); with chemoimmunotherapy backbones (blinatumomab, inotuzumab), IT doses may need to increase to ≥15 to prevent unmasked CNS relapse ³⁵
Delaying or omitting molecular/cytogenetic testing that determines treatment selection	FLT3-ITD/TKD determines midostaurin/quizartinib eligibility (AML); BCR::ABL1 determines TKI use (ALL); CAP/ASH recommends integrated reporting within 2 weeks ; ^{12,13} do not begin AML induction without at least FLT3 and cytogenetics, as this forecloses targeted agent addition
Defaulting to intensive induction in older/unfit AML without fitness assessment	Chronological age alone is inadequate ; ¹ NCCN recommends evaluating PS, comorbidities, and organ function for patients ≥60 ; ¹⁵ ASH recommends HMA + venetoclax over HMA alone for patients unfit for conventional induction ; ³⁶ document rationale for intensity selection including ECOG PS and comorbidity burden
Not coding complications (DIC, TLS, febrile neutropenia) alongside the leukemia	Complications carry independent clinical and coding significance; code each: D65 (DIC), E88.3 (TLS), D70.1 + R50.81 (febrile neutropenia), D61.810 (pancytopenia)

OVERSIGHT/SHORTCUT

WHY IT MATTERS — WHAT TO DO INSTEAD^{3,12-15}

ABBREVIATIONS: CBC = complete blood count; AML = acute myeloid leukemia; APL = acute promyelocytic leukemia; ATRA = all-trans retinoic acid; DIC = disseminated intravascular coagulation; HLA-DR = human leukocyte antigen-DR isotype; WBC = white blood cell count; RBC = red blood cell; CNS = central nervous system; ALL = acute lymphoblastic leukemia; HD-MTX = high-dose methotrexate; IT = intrathecal; FLT3-ITD/TKD = FMS-like tyrosine kinase 3-internal tandem duplication/tyrosine kinase domain; BCR::ABL1 = breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 fusion; TKI = tyrosine kinase inhibitor; CAP = College of American Pathologists; ASH = American Society of Hematology; NCCN = National Comprehensive Cancer Network; PS = performance status; HMA = hypomethylating agent; ECOG = Eastern Cooperative Oncology Group; TLS = tumor lysis syndrome

Key Differentials in Elderly

PRESENTATION	DIFFERENTIAL	KEY TESTS ^{14,15,18,35,37,38}
Pancytopenia with fatigue and infection	Myelodysplastic syndrome (MDS), aplastic anemia, drug-induced marrow suppression	Bone marrow aspirate with cytogenetics; medication reconciliation; B12/folate levels ³
Leukocytosis with left shift and fever	Leukemoid reaction (severe infection), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL)	Peripheral smear for blasts vs. bands; LAP score; BCR-ABL qPCR ; flow cytometry
Isolated anemia in older adult	Anemia of chronic disease, iron deficiency, B12/folate deficiency, MDS, early AML	Reticulocyte count, iron studies, B12/folate; bone marrow if persistent or progressive
Bleeding or petechiae with thrombocytopenia	ITP, TTP, DIC from sepsis, drug-induced thrombocytopenia, APL	Coagulation panel with D-dimer and fibrinogen; peripheral smear for schistocytes or blasts
Bone pain in older adult with cytopenias	Multiple myeloma, metastatic bone disease, AML with marrow infiltration	SPEP/UPEP with free light chains; skeletal imaging; bone marrow biopsy

ABBREVIATIONS: ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; APL = acute promyelocytic leukemia; BCR-ABL = breakpoint cluster region-Abelson fusion gene; CLL = chronic lymphocytic leukemia; CML = chronic myeloid leukemia; DIC = disseminated intravascular coagulation; ITP = immune thrombocytopenia; LAP = leukocyte alkaline phosphatase; MDS = myelodysplastic syndrome; SPEP = serum protein electrophoresis; TB = tuberculosis; TTP = thrombotic thrombocytopenic purpura; UPEP = urine protein electrophoresis



CLINICAL PEARL — CLUES TO DIG DEEPER

New, unexplained **pancytopenia** is the hallmark presentation of bone marrow failure from acute leukemia in older adults and should never be dismissed as '**age-related**' or a presumed infectious delay diagnosis.³⁹ A peripheral blood smear with CBC and differential takes minutes; circulating blasts, Auer rods, or unexplained immature granulocytes warrant same-day hematology contact and bone marrow biopsy, not watchful waiting.^{15,25} **This single low-cost screening step** is the gateway to timely risk stratification, targeted therapy selection, and avoidance of downstream emergency presentations (leukostasis, DIC, TLS) that drive preventable inpatient utilization.

Comorbidity Screening

CONDITION	PREVALENCE IN THIS POPULATION ^{15,36,36,40}	SCREENING APPROACH ^{15,36,36,40}
Cardiovascular disease/LV dysfunction	CVD associated with mOS 26 vs. 12 mo (p=0.005); LVEF ≤50% excludes intensive 7+3 induction (Ferrara criteria) ³⁹	Baseline echocardiogram before anthracycline therapy; cardiology co-management if prior CAD or HF ³⁹
Cognitive impairment	MMSE dysfunction predicts grade 3–4 infections and prolonged hospitalization ≥40 days (p=0.005) ⁴¹	Mini-Cog (2–3 min) at initial assessment; MoCA if screen-positive ⁴⁰
Depression	Depressive symptoms associated with inferior OS (p=0.048); 64% baseline positive screen in elderly AML	GDS-4 or PHQ-2 (<2 min); PHQ-9 if positive; treat as part of supportive care
Renal impairment (CrCl <45 mL/min)	Excludes intensive 7+3 induction	Baseline CrCl; dose adjust cytarabine per NCCN (≥2 g/m ² contraindicated in renal failure); LDAC + glasdegib is an approved option in advanced CKD
Frailty and functional decline	SPPB <9 predicts inferior OS (p=0.027); Fried phenotype: 2-yr OS 57% fit/42% pre-frail/21% frail	SPPB (<5 min) pre-treatment and at intensification points; add gait speed and grip strength ⁴²

ABBREVIATIONS: AKI = acute kidney injury; AML = acute myeloid leukemia; CAD = coronary artery disease; CKD = chronic kidney disease; CrCl = creatinine clearance; CVD = cardiovascular disease; CYP3A4 = cytochrome P450 3A4; GDS-4 = Geriatric Depression Scale 4-item; HF = heart failure; HR = hazard ratio; LDAC = low-dose cytarabine; LV = left ventricular; LVEF = left ventricular ejection fraction; MMSE = Mini-Mental State Examination; MoCA = Montreal Cognitive Assessment; mOS = median overall survival; OS = overall survival; PHQ = Patient Health Questionnaire; SPPB = Short Physical Performance Battery

Staging and Risk Stratification Systems for AML and ALL

Unlike solid tumors, acute leukemias (AML and ALL) **do not** use traditional TNM staging. Instead, the gold standard in US practice is **genetic/molecular risk stratification**, which directly determines treatment intensity and post-remission strategy.²⁷

Gold Standard Risk Stratification - AML (ELN 2022)

RISK CATEGORY ²⁷	KEY GENETIC ABNORMALITIES ²⁷	EXPECTED OUTCOMES (INTENSIVE TX) ²⁷	TREATMENT IMPLICATIONS ²⁷
Favorable	t(8;21)/RUNX1::RUNX1T1; inv(16)/CBFB::MYH11; mutated NPM1 without FLT3-ITD; bZIP in-frame mutated CEBPA	Younger: CR ~86%, 3-yr OS ~75%; Age >60: CR ~81%, 3-yr OS ~45%	Consolidation chemotherapy (HiDAC ± GO); HCT generally not recommended in CR1 unless MRD+
Intermediate	NPM1 with FLT3-ITD; wild-type NPM1 with FLT3-ITD (no adverse lesions); t(9;11)/MLLT3::KMT2A; abnormalities not classified as favorable or adverse	Younger: CR ~59%, 3-yr OS ~45%; Age >60: CR ~50%, 3-yr OS ~18%	HCT considered on case-by-case basis ; MRD status critical for HCT decision
Poor/Adverse	Complex/monosomal karyotype; -5/del(5q), -7, -17/abn(17p); KMT2A-r (non-t[9;11]); BCR::ABL1; inv(3); mutated TP53 (VAF ≥10%); myelodysplasia-related mutations (ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, ZRSR2)	Younger: CR ~49%, 3-yr OS ~28%; Age >60: CR ~32%, 3-yr OS ~4%	HCT preferred in CR1; TP53-mutated → clinical trial recommended ; CPX-351 preferred for therapy-related/MDS-related AML age ≥60

ABBREVIATIONS: TX = treatment; CR = complete remission; OS = overall survival; HiDAC = high-dose cytarabine; GO = gemtuzumab ozogamicin; HCT = hematopoietic cell transplantation; CR1 = first complete remission; MRD = measurable residual disease; FLT3-ITD = FLT3 internal tandem duplication; KMT2A-r = KMT2A-rearranged; BCR::ABL1 = breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 fusion; TP53 = tumor protein p53; VAF = variant allele frequency; ASXL1 = additional sex combs-like 1; BCOR = BCL6 corepressor; EZH2 = enhancer of zeste homolog 2; RUNX1 = RUNX family transcription factor 1; SF3B1 = splicing factor 3b subunit 1; SRSF2 = serine/arginine-rich splicing factor 2; STAG2 = stromal antigen 2; U2AF1 = U2 small nuclear RNA auxiliary factor 1; ZRSR2 = zinc finger CCCH-type, RNA binding motif and serine/arginine rich 2; CPX-351 = liposomal daunorubicin-cytarabine; MDS = myelodysplastic syndrome; AML = acute myeloid leukemia; NPM1 = nucleophosmin 1; CEBPA = CCAAT/enhancer-binding protein alpha; CBFB::MYH11 = core-binding factor subunit beta-myosin heavy chain 11 fusion; RUNX1::RUNX1T1 = RUNX family transcription factor 1-RUNX1 partner transcriptional co-repressor 1 fusion; MLLT3::KMT2A = MLLT3 super elongation complex subunit-lysine methyltransferase 2A fusion

Gold Standard Risk Stratification - B-ALL (NCCN Cytogenetic/Molecular)

RISK CATEGORY ¹⁴	KEY CYTOGENETIC/MOLECULAR ALTERATIONS ¹⁴	TREATMENT IMPLICATIONS ¹⁴
Standard risk	Hyperdiploidy (51-65 chromosomes); t(12;21)/ETV6::RUNX1; t(1;19)/TCF3::PBX1; DUX4-r; PAX5 P80R; BCR::ABL1 without IKZF1-plus and without antecedent CML	Consolidation chemotherapy + blinatumomab (preferred per ECOG 1910); HCT considered if MRD persists
Poor risk	Hypodiploidy (44 chromosomes); TP53 mutation; KMT2A-r; Ph-like ALL (JAK-STAT, ABL class); BCR::ABL1 with IKZF1-plus or antecedent CML; iAMP21; IKZF1 alterations; complex karyotype (≥ 5 abnormalities); IgH-r, HLF-r, MYC-r, ZNF384-r, MEF2D-r, PAX5alt	HCT favored in CR1, especially with slow/incomplete MRD clearance; blinatumomab for MRD+ disease

ABBREVIATIONS: ETV6::RUNX1 = ETS variant transcription factor 6-RUNX family transcription factor 1 fusion; TCF3::PBX1 = transcription factor 3-pre-B-cell leukemia transcription factor 1 fusion; DUX4-r = DUX4-rearranged; PAX5 = paired box 5; BCR::ABL1 = breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 fusion; IKZF1 = IKAROS family zinc finger 1; CML = chronic myeloid leukemia; ECOG = Eastern Cooperative Oncology Group; HCT = hematopoietic cell transplantation; MRD = measurable residual disease; TP53 = tumor protein p53; KMT2A-r = KMT2A-rearranged; Ph = Philadelphia chromosome; ALL = acute lymphoblastic leukemia; JAK-STAT = Janus kinase-signal transducer and activator of transcription; ABL = Abelson murine leukemia viral oncogene; iAMP21 = intrachromosomal amplification of chromosome 21; IgH-r = immunoglobulin heavy chain-rearranged; HLF-r = hepatic leukemia factor-rearranged; MYC-r = MYC proto-oncogene-rearranged; ZNF384-r = zinc finger protein 384-rearranged; MEF2D-r = myocyte enhancer factor 2D-rearranged; PAX5alt = PAX5 alterations; CR1 = first complete remission

Alternative Staging/Severity Metrics Used in US Practice

METRIC	APPLIES TO	WHAT IT MEASURES	CLINICAL ROLE IN US PRACTICE
MRD by MFC ($\geq 10^{-3}$) ^{14,15}	AML and ALL	Residual leukemic cells by flow cytometry after morphologic CR	Prognostic: MRD ⁻ vs. MRD ⁺ → 5-yr OS 68% vs. 34% (AML); strongest relapse predictor in ALL; guides HCT decisions and post-remission therapy
MRD by NGS ($\geq 10^{-5}$ to 10^{-6}) ^{14,15}	AML (FLT3-ITD) and ALL	Ultra-sensitive detection of clonal rearrangements or mutations	NCCN recommends NGS-based MRD for FLT3-ITD AML; preferred method in ALL (FDA-approved Ig/TCR assay); confirms negativity when flow is negative
MRD by RQ-PCR ($\geq 10^{-4}$) ¹⁵	AML (NPM1, CBF, PML::RARA)	Molecular transcript quantification for specific fusion genes	NCCN recommends serial monitoring q6-12 weeks × 24 months for NPM1, CBFB::MYH11, RUNX1::RUNX1T1; q3 months × 24 months for PML::RARA
WHO/ICC 2022 Classification ^{26,43}	AML and ALL	Morphologic, immunophenotypic, and genomic disease subtyping	Defines disease entities (e.g., AML with defining genetic abnormalities vs. AML defined by differentiation); complements ELN risk for diagnostic categorization

METRIC	APPLIES TO	WHAT IT MEASURES	CLINICAL ROLE IN US PRACTICE
NCI Risk Criteria (age/WBC) ¹⁴	B-ALL (primarily pediatric, applied in AYA)	Age 35 y + WBC $30 \times 10^9/L$ (B-ALL) = standard risk; age ≥ 35 or WBC $\geq 30 \times 10^9/L$ = high risk	Traditional clinical risk assignment; now largely superseded by molecular classification in adults but still used for initial stratification in some protocols
ECOG Performance Status ¹⁵	AML and ALL	Functional status (0–4 scale)	Determines intensive induction eligibility; NCCN uses PS alongside comorbidities and organ function for fitness assessment in AML ≥ 60 y
Geriatric Assessment (SPPB, G8) ^{36,40}	AML (older adults)	Physical function, frailty, cognition, comorbidities	ASH recommends HMA + venetoclax over intensive induction for unfit patients; SPPB 9 predicts inferior OS
LSC17 Score ^{44,44}	AML	17-gene leukemic stem cell expression signature	Independently predicts CR, MRD, RFS, and OS beyond ELN 2022; high score identifies patients benefiting from HCT; emerging but not yet in guidelines

ABBREVIATIONS: ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; APL = acute promyelocytic leukemia; AYA = adolescent and young adult; BM = bone marrow; CBF = core-binding factor; CML = chronic myeloid leukemia; CR = complete remission; CR1 = first complete remission; ELN = European LeukemiaNet; ETP = early T-cell precursor; FISH = fluorescence in situ hybridization; GO = gemtuzumab ozogamicin; HCT = hematopoietic cell transplantation; HiDAC = high-dose cytarabine; HMA = hypomethylating agent; iAMP21 = intrachromosomal amplification of chromosome 21; ICC = International Consensus Classification; MFC = multicolor flow cytometry; MRD = measurable residual disease; NCCN = National Comprehensive Cancer Network; NCI = National Cancer Institute; NGS = next-generation sequencing; OS = overall survival; Ph = Philadelphia chromosome; PS = performance status; RFS = relapse-free survival; RQ-PCR = real-time quantitative polymerase chain reaction; SPPB = Short Physical Performance Battery; TKI = tyrosine kinase inhibitor; TX = treatment; VAF = variant allele frequency; WBC = white blood cell; WHO = World Health Organization

**RED FLAG — EMERGENCY/ACTIVATE CRISIS RESPONSE**

These emergency conditions require **same-day specialist or ED referral** for patients with known or suspected acute leukemia:

- **Suspected APL with coagulopathy (DIC)**
 - → Start ATRA immediately upon first morphologic suspicion, **do not** wait for cytogenetic confirmation; maintain platelets $\geq 50 \times 10^9/L$ and fibrinogen > 150 mg/dL with aggressive transfusion support; avoid central line placement during active coagulopathy
 - × **Delayed ATRA initiation is independently associated with early hemorrhagic death**
- **Hyperleukocytosis with leukostasis** (WBC $> 100 \times 10^9/L$ with dyspnea, hypoxemia, confusion, or focal neurologic deficits; monocytic AML may manifest at $> 50 \times 10^9/L$)
 - → Initiate hydroxyurea immediately; avoid RBC transfusion until WBC is reduced; leukapheresis may be considered for symptomatic leukostasis
 - × **20-40% first-week mortality with leukostasis**
- **Febrile neutropenia (ANC $< 500/\mu L$ + temperature $\geq 38.3^\circ C$ or $\geq 38.0^\circ C$ sustained ≥ 1 hour)**
 - → Administer empiric broad-spectrum antipseudomonal antibiotics within 1 hour of triage (cefepime, meropenem, or piperacillin-tazobactam; **category 1**); obtain blood cultures but do not delay antibiotics for specimen collection
- **Tumor lysis syndrome (rising creatinine, hyperkalemia, hyperuricemia, hyperphosphatemia)**
 - → Aggressive IV hydration (1.5–2× maintenance); rasburicase for high-risk patients (WBC $> 100 \times 10^9/L$, elevated LDH $> 2 \times$ ULN, renal dysfunction); check **G6PD status** when feasible; continuous cardiac monitoring for hyperkalemia; consider hemodialysis/CRRT if electrolytes do not correct
- **Circulating blasts on peripheral smear or unexplained pancytopenia**
 - → Same-day hematology contact; do not wait for bone marrow confirmation to initiate referral; a single circulating blast is diagnostic until proven otherwise



RED FLAG — RAPID DECLINE/RATE-OF-CHANGE WARNING

Rapid clinical deterioration in a patient with known or suspected leukemia warrants immediate re-evaluation:

- **New confusion, altered mental status, severe headache, or focal neurologic deficits**
 - → Evaluate for CNS leukemia (LP with cytology/flow if safe), intracranial hemorrhage (emergent CT), or leukostasis; CNS involvement occurs in ~5–8% of adult ALL and requires urgent intrathecal therapy
- **Worsening dyspnea with pulmonary infiltrates in a patient on ATRA, IDH inhibitors, or menin inhibitors**
 - → Suspect **differentiation syndrome** = initiate dexamethasone 10 mg BID immediately; consider interrupting the offending agent until hypoxia resolves; IDH inhibitor-associated DS can occur up to several months after induction and is reported in ~19% of patients
- **Rising creatinine with hyperkalemia and hyperuricemia during or shortly after initiating therapy**
 - **Tumor lysis syndrome** = escalate hydration, administer rasburicase, and initiate continuous metabolic monitoring; consider nephrology consultation for CRRT if refractory
- **New petechiae, mucosal bleeding, or hematuria with worsening thrombocytopenia or coagulopathy**
 - → Evaluate for DIC (fibrinogen, D-dimer, PT/aPTT); in APL, maintain platelets $\geq 50 \times 10^9/L$ and fibrinogen >150 mg/dL; in non-APL AML, transfuse platelets for counts $<10 \times 10^9/L$ or any active bleeding
- **Functional decline on active treatment in older adults**
 - → Expedited geriatric assessment to identify reversible causes (infection, delirium, polypharmacy, uncontrolled pain); reassess fitness for continued intensive therapy vs. transition to lower-intensity regimen (HMA + venetoclax)



AAVBC PERSPECTIVE

Recognition of acute leukemia begins with **pattern awareness**, there is no population-level screening test. Unexplained fatigue, recurrent infections, easy bruising, and bone pain should **raise suspicion**, especially when paired with pallor, petechiae, or hepatosplenomegaly. In older adults, progressive fatigue is frequently misattributed to aging, delaying recognition. When a CBC reveals pancytopenia, circulating blasts, or severe unexplained cytopenia, **the pathway is clear**: peripheral smear review by a pathologist within 24–48 hours and expedited hematology referral for marrow evaluation. Care teams with standing workflows for abnormal CBC escalation and clear red-flag communication: fever with neutropenia, new blasts,

*unexplained bleeding = **reduce time-to-diagnosis**. Earlier recognition directly improves outcomes, particularly in acute promyelocytic leukemia where prompt treatment prevents fatal coagulopathy.*

3 MEAT DOCUMENTATION ESSENTIALS

Accurate acute leukemia documentation translates clinical complexity into a record that supports personalized care delivery, continuity, and appropriate care planning. The most common documentation failures are "history of" framing for active disease under treatment, under-coded treatment-related cytopenias, and omission of functional status trends that drive care planning. The MEAT framework below ties each element into appropriate clinical action:

*A 72-year-old female with ELN 2022 **intermediate-risk AML** on maintenance azacitidine + venetoclax (VIALE-A-based regimen) after lower-intensity induction, diagnosed 9 months ago. Presents for routine PCP follow-up; reports **fatigue, no fever, no new bleeding**. Oncology CBC two weeks prior: ANC 1,200, Hgb 10.2, platelets 92,000. SPPB declined from 9 to 7 over 3 months.*

MONITOR: "CBC from [date]: ANC 1,200/ μ L, Hgb 10.2 g/dL, platelets 92,000/ μ L. BMP within baseline. SPPB today = 7 (prior 9, 3 months ago). Venetoclax cycle 10, day 14; azacitidine 75 mg/ m^2 SC days 1–7 at oncology infusion center."

EVALUATE: "Persistent cytopenias consistent with expected treatment effect, **not relapse**. No infectious signs, bleeding, or bone pain. Functional decline (SPPB 9 $\rightarrow$ 7) — gait speed and balance reduced; concerning cumulative treatment toxicity. No cognitive concerns per patient and daughter. Treatment goals and QoL priorities unchanged."

ASSESS: "1) AML (**C92.01**), ELN 2022 intermediate risk, complete remission on maintenance azacitidine + venetoclax per hematology (Dr. [Name], last seen [date]). 2) Chemotherapy-induced pancytopenia (D61.810). 3) Functional decline on treatment — geriatric reassessment indicated."

TREAT: "Continue oncology regimen as directed. Venetoclax adherence reinforced: with food, same time daily, no grapefruit; medication reconciliation confirms no new CYP3A4 inhibitors. PT referral for functional decline. ACP on file, reviewed, no changes. Return 6 weeks; call for fever $\geq 38.0^\circ\text{C}$ or new bleeding."

Clinical Documentation Elements

- **Link clinical relationships:** Document the connection between leukemia and concurrent complications: e.g., 'Chemotherapy-induced pancytopenia (**D61.810**) due to maintenance therapy for AML (**C92.01**).' = supports the **severity of the clinical picture** and accurate coding of both the leukemia and its complications¹⁵
- **Include current data:** Document the most recent CBC with date (ANC, Hgb, platelets), basic metabolic panel, and functional measure (SPPB or ECOG); required **every encounter** during the reporting year¹⁵
- **Specify precisely:** Always state cell type (AML vs. ALL), ELN 2022 risk category when known, and 6th-character remission status; **avoid** 'acute leukemia unspecified' (**C95.0x**) once pathology has returned

- **Document chronicity:** Note diagnosis date, current cycle/phase of treatment, and duration in remission when applicable = distinguishes active surveillance from true 'history of' status^{14,15}
- **Associated conditions:** List co-present complications: febrile neutropenia (**D70.1 + R50.81**), TLS (**E88.3**), DIC (**D65**), anemia due to chemotherapy (**D64.81**); each carries independent clinical significance

Reframing Common Documentation Shortcuts

INSTEAD OF...	DOCUMENT...
'Acute leukemia'	'Acute myeloid leukemia (AML), ELN 2022 [risk], [6th-char status]'; always specify lineage and current remission status once known ^{14,15}
'History of leukemia' (while on maintenance)	'AML in complete remission on maintenance azacitidine + venetoclax': use C92.01, not Z85.6 , until all active therapy has ended ^{14,15}
'AML, no treatment today'	'AML, active surveillance with defined monitoring interval: CBC every 4 weeks, bone marrow every 6 months per hematology'
'Fever and low counts'	'Febrile neutropenia: temperature 38.6°C, ANC 320/μL, on maintenance venetoclax for AML' (D70.1 + R50.81 + C92.01) ^{14,15}
'Doing fine on chemo'	'Patient tolerating cycle 10 of azacitidine + venetoclax; ANC 1,200, Hgb 10.2, platelets 92,000; SPPB 7 (declined from 9); advance care plan reviewed, no changes'

ABBREVIATIONS: AML = acute myeloid leukemia; ANC = absolute neutrophil count; CBC = complete blood count; ELN = European LeukemiaNet; MEAT = monitor/evaluate/assess/treat; SPPB = Short Physical Performance Battery



DOCUMENTATION IS COMPREHENSIVE CODING

Every active acute leukemia encounter should state the diagnosis with subtype specificity (**C91.01** ALL in remission; **C92.01** AML in remission), code treatment-related cytopenias (**D61.810**), record current functional status (ECOG, SPPB), describe the active management plan (regimen, cycle, dose modifications, toxicity), and list comorbidity linkages (tumor lysis prophylaxis, infection risk management, transfusion dependence **D64.81**, treatment-related fatigue **R53.0**, functional decline **Z74.09**). Each line of documentation corresponds to clinical work the care team is actually performing.

4 TREATMENT AND REFERRAL QUICK GUIDE

Acute leukemia management in older adults has shifted meaningfully over the last decade: the transition from uniform 7+3 induction to a **fitness-based decision** between intensive therapy and lower-intensity HMA + venetoclax represents the most consequential change in a generation, and it aligns directly with **value-based care goals** of delivering the right dose for the right patient while minimizing avoidable hospital utilization burden.^{15,25,36}

Therapy Escalation Criteria

TRIGGER	ACTION
Circulating blasts on peripheral smear OR unexplained pancytopenia OR WBC >50,000/μL with abnormal differential	Same-day hematology contact; If patient unstable → ED transfer: initiate CBC, CMP, LDH, uric acid, coagulation panel, type and screen while arranging specialist contact ²⁵
Suspicion of APL (coagulopathy + blasts + fibrinogen <150)	Hematology emergency: Start ATRA immediately if available; arrange immediate transfer to specialized center; DIC management (cryoprecipitate, FFP, platelets) in parallel ¹⁵
Febrile neutropenia (T $\geq$38.3°C once OR $\geq$38.0°C sustained AND ANC <500/μL)	Blood cultures $\times$ 2, urinalysis/culture, chest imaging; empiric broad-spectrum antibiotics within 60 minutes of recognition per NCCN ¹⁵
TLS signs (rising creatinine, hyperkalemia, hyperuricemia, hypocalcemia) during venetoclax ramp-up	Aggressive IV hydration, rasburicase (high-risk patients), electrolyte correction, cardiac monitoring.; hold or slow venetoclax ramp per specialist ¹⁵
Rapid SPPB decline, new falls, or functional loss on treatment	Reassess fitness and treatment goals; consider de-escalation or palliative care integration→ full geriatric assessment ^{42,45}

ABBREVIATIONS: ANC = absolute neutrophil count; APL = acute promyelocytic leukemia; ATRA = all-trans retinoic acid; CBC = complete blood count; CMP = comprehensive metabolic panel; DIC = disseminated intravascular coagulation; FFP = fresh frozen plasma; LDH = lactate dehydrogenase; NCCN = National Comprehensive Cancer Network; SPPB = Short Physical Performance Battery; TLS = tumor lysis syndrome; WBC = white blood cell count

NCCN/ASH 2025 Aligned Recommendations

CATEGORY	RECOMMENDED TREATMENT ^{14,15,36}	PCP ACTIONS ^{14,15,36}
AML, Fit patients (good functional status, no major organ dysfunction)	Intensive chemotherapy (7+3 regimen) $\pm$ targeted agents if specific mutations present (FLT3 , CD33)	Confirm geriatric assessment completed for patients $\geq$ 60; expect prolonged inpatient stays ; coordinate post-discharge follow-up; monitor for infection, bleeding, and transfusion needs between cycles

CATEGORY	RECOMMENDED TREATMENT ^{14,15,36}	PCP ACTIONS ^{14,15,36}
AML, Unfit or ≥ 75 or patient preference	Azacitidine + venetoclax (oral); outpatient-based regimen	Most common regimen PCPs will encounter at follow-up; monitor CBC trends, reinforce venetoclax adherence (take with food, avoid grapefruit, check for CYP3A4 drug interactions at every visit); watch for tumor lysis syndrome signs early in treatment
APL (a distinct, highly curable subtype; E92.4(0/1/2))	ATRA + arsenic trioxide; anthracycline added for high-WBC disease	Hematologic emergency: if APL is suspected (young patient, DIC, blasts on smear), initiate ATRA immediately and refer same day ; cure rates exceed 90% with prompt treatment
ALL, Ph-negative	Intensive multi-agent chemotherapy; blinatumomab may be added	Patients ≥ 60 require significant dose reductions and closer toxicity monitoring ; expect frequent lab checks; coordinate with oncology on neutropenic precautions and infection management
ALL, Ph-positive	Targeted oral TKI (dasatinib or ponatinib) + chemotherapy backbone; blinatumomab-based regimens in older adults	TKI-based therapy is generally better tolerated than intensive chemo in older patients; PCP role : medication reconciliation for TKI drug interactions, blood pressure monitoring (ponatinib), and cardiovascular risk assessment

ABBREVIATIONS: AML = acute myeloid leukemia; FLT3 = FMS-like tyrosine kinase 3; CD33 = cluster of differentiation 33; PCP = primary care provider; CBC = complete blood count; CYP3A4 = cytochrome P450 3A4; APL = acute promyelocytic leukemia; ATRA = all-trans retinoic acid; WBC = white blood cell count; DIC = disseminated intravascular coagulation; ALL = acute lymphoblastic leukemia; Ph = Philadelphia chromosome; TKI = tyrosine kinase inhibitor

Non-Pharmacologic Treatment and Lifestyle Modification

INTERVENTION	TARGET/RECOMMENDATION	NOTES
Geriatric assessment + targeted interventions	Every patient ≥ 60 years before treatment decisions	G-8 screen (4–5 min); SPPB, Mini-Cog, GDS-4 if screen ≤ 14 ; GA-guided interventions reduced early mortality in phase II data ⁴⁶
Nutrition optimization	Mini Nutritional Assessment; dietitian referral if at-risk	At-risk status independently associated with mortality (HR 2.00) in older hematologic malignancies ⁴⁷
Physical function support	Physical therapy for SPPB < 9 ; fall-prevention program	Gait-speed and sit-to-stand training; pre-habilitation before intensive therapy where feasible ⁴²

INTERVENTION	TARGET/RECOMMENDATION	NOTES
Early palliative care integration (concurrent, not end-of-life)	At diagnosis for all elderly patients with acute leukemia	ASH 2025: palliative care improves symptom burden and treatment tolerability; may access Part B palliative transfusions outside hospice ³⁶
ABBREVIATIONS: G-8 = Geriatric 8 screening tool; SPPB = Short Physical Performance Battery; GDS-4 = Geriatric Depression Scale 4-item; GA = geriatric assessment; HR = hazard ratio; ASH = American Society of Hematology		

Non-Pharmaceutical Prevention Strategies

Acute leukemia is **not amenable** to primary prevention in most cases. Secondary prevention focuses on **reducing treatment-related mortality**: early recognition of febrile neutropenia, infection prophylaxis per specialist protocol, TLS prophylaxis (hydration, rasburicase, allopurinol), and cardioprotection with baseline echocardiography before anthracyclines. Surveillance of CHIP-positive patients for cardiovascular risk may reduce non-leukemia mortality in survivors.³

Medication Safety Considerations

AGENT/CLASS	INTERACTION/TOXICITY*	PCP ACTION
Venetoclax + strong azole antifungals (voriconazole, posaconazole)	Venetoclax levels ↑ 5-6-fold; prolonged severe cytopenias; HIGH risk	Verify oncology has reduced venetoclax by 75%; CBC weekly during co-administration; flag at every medication reconciliation
Venetoclax + moderate CYP3A4 inhibitors (diltiazem, verapamil, erythromycin, grapefruit juice)	Venetoclax levels ↑ ~2-fold; worsened cytopenias; MODERATE risk	Counsel to avoid grapefruit juice throughout therapy; flag diltiazem/verapamil at medication reconciliation; increase CBC frequency
Anthracyclines (daunorubicin, idarubicin)	Cumulative cardiotoxicity; HIGH risk if LVEF ≤50% (contraindication)	Ensure baseline echocardiogram on file; reassess before each course; coordinate with cardio-oncology if EF borderline
High-dose cytarabine (≥2 g/m²) in patients ≥60 or CrCl 45	Cerebellar neurotoxicity (nystagmus, slurred speech, gait instability); HIGH risk	Ask about new balance or coordination problems at every visit; report neurologic changes to oncology immediately
HMA + venetoclax in CKD (CrCl 45)	Impaired uric acid clearance → tumor lysis syndrome → AKI; HIGH risk	Confirm TLS prophylaxis in place during ramp-up; monitor daily uric acid + CMP during first cycle; AKI independently predicts worse OS (HR 1.86)

AGENT/CLASS	INTERACTION/TOXICITY*	PCP ACTION
Live vaccines during active therapy	Impaired immune response; risk of live-virus replication; CONTRAINDICATED	Defer all live vaccines during treatment; administer inactivated influenza and pneumococcal vaccines before initiation when feasible; document immunization history at diagnosis
Polypharmacy (≥5 medications) in older adults	Unpredictable drug interactions; adherence complexity; MODERATE-HIGH risk	Comprehensive medication reconciliation at every visit; pharmacist consult; deprescribe where possible; adherence check for venetoclax (take with food, same time daily)

ABBREVIATIONS: AKI = acute kidney injury; CBC = complete blood count; CKD = chronic kidney disease; CMP = comprehensive metabolic panel; CrCl = creatinine clearance; CYP3A4 = cytochrome P450 3A4; EF = ejection fraction; HMA = hypomethylating agent; HR = hazard ratio; LVEF = left ventricular ejection fraction; OS = overall survival; TLS = tumor lysis syndrome.

***Consult FDA labels for the most up-to-date dosage information, contraindications, and drug-drug interactions**

When to Refer

CRITERION ^{14,15,25,36}	SPECIALIST	URGENCY ^{14,15,25,36}
Circulating blasts on peripheral smear	Hematology/oncology	ASAP or refer to hospital
Unexplained pancytopenia, suspected marrow failure	Hematology/oncology	ASAP or refer to hospital
Coagulopathy + blasts (suspect APL)	Hematology emergency + ED	IMMEDIATE: start ATRA on suspicion
LVEF ≤50% before planned anthracycline therapy	Cardio-oncology	Before therapy initiation
Functional decline, frailty, or geriatric domain impairment	Geriatric oncology or geriatrics consult	Before treatment decision; and at intensification points

ABBREVIATIONS: APL = acute promyelocytic leukemia; ATRA = all-trans retinoic acid; ED = emergency department; LVEF = left ventricular ejection fraction

Follow-Up Timing

STAGE/ CATEGORY ^{14,15,25,36}	FREQUENCY	LABS TO MONITOR ^{14,15,25,36}
Active induction (fit, intensive)	Daily inpatient; CBC/CMP ≥ daily; coagulation daily if APL	CBC with diff, CMP, LDH, uric acid, coagulation panel (PT/aPTT/fibrinogen/D-dimer)
Venetoclax ramp-up period (outpatient or brief inpatient)	CBC/CMP 2× weekly; daily uric acid in high-risk TLS	CBC, CMP, uric acid, phosphate, calcium
Post-induction consolidation/maintenance (HMA + venetoclax)	CBC weekly early; then every 2-4 weeks per cycle	CBC, CMP, echocardiogram annually or before re-induction
Complete remission: post-treatment surveillance	Every 1-3 months for first 2 years; every 6 months thereafter (per oncology)	CBC with diff; bone marrow at specialist discretion; document remission status each visit
Best supportive care	Every 2-4 weeks or per symptom-driven schedule	CBC to guide transfusion support; symptom burden assessment

ABBREVIATIONS: aPTT = activated partial thromboplastin time; APL = acute promyelocytic leukemia; CBC = complete blood count; CMP = comprehensive metabolic panel; HMA = hypomethylating agent; LDH = lactate dehydrogenase; MEAT = monitor/evaluate/assess/treat; PT = prothrombin time; TLS = tumor lysis syndrome

Comorbidity Management

COMORBIDITY ^{14,15,25,36}	APPROACH ^{14,15,25,36}	CAUTION ^{14,15,25,36}
Heart failure/LV dysfunction	Avoid anthracyclines if LVEF ≤50% ; select HMA + venetoclax or FLAG-based therapy	Baseline echo mandatory; cardiology co-management ³⁹
Chronic kidney disease (CrCl <45 mL/min)	LDAC + glasdegib is an approved option; dose-adjust cytarabine; careful TLS prophylaxis	AKI during HMA + venetoclax independently predicts mortality (HR 1.86); sepsis more frequent ⁴⁸
Cognitive impairment	Mini-Cog at baseline; caregiver engagement essential for oral venetoclax adherence	MMSE dysfunction predicts grade 3-4 infections and prolonged hospitalization (≥40 days, p=0.005) ⁴¹
Diabetes + steroid-containing regimens (corticosteroid in ALL, dexamethasone)	Glycemic management with endocrinology; adjust insulin/oral agents during treatment	Hyperglycemia can mimic or mask infection; increased insulin needs during induction ¹⁷

COMORBIDITY ^{14,15,25,36}	APPROACH ^{14,15,25,36}	CAUTION ^{14,15,25,36}
Polypharmacy and CYP3A4 inhibitor exposure	Pharmacist consult; venetoclax dose adjustment per interaction tier*	At least 50% dose reduction for moderate inhibitors;* 75% for strong inhibitors*
ABBREVIATIONS: AKI = acute kidney injury; ALL = acute lymphoblastic leukemia; CrCl = creatinine clearance; CYP3A4 = cytochrome P450 3A4; FLAG = fludarabine/cytarabine/G-CSF; HMA = hypomethylating agent; HR = hazard ratio; LDAC = low-dose cytarabine; LV = left ventricular; LVEF = left ventricular ejection fraction; MMSE = Mini-Mental State Examination. *Consult FDA labels for the most up-to-date dosage information, contraindications, and drug-drug interactions		

Cost-Smart Options

BRAND (EST. COST) ⁴⁹⁻⁵¹	GENERIC/ALTERNATIVE (EST. COST) ^{49,52}	EST. MONTHLY SAVINGS	COST-SMART TIP (MEDICARE COVERAGE) ^{5,53,54}
Venclexta (venetoclax) 400 mg/day (~\$8,000-\$10,000 /mo)	Available soon Est. May 2026	N/A	(Part D); manufacturer copay assistance and patient assistance programs available; coordinate social work referral early; no generic expected near-term
Vidaza (azacitidine) 75 mg/m² SC/IV days 1-7 (~\$9,800/cycle brand)	Generic azacitidine SC/IV (~\$650-\$8,600 /cycle depending on source)	~\$1,200-\$9,000/cycle	(Part B; infusion); generic azacitidine widely available ; verify formulary tier; biosimilar use where appropriate
Dacogen (decitabine) 20 mg/m² IV days 1-5 (~\$10,800/cycle brand)	Generic decitabine IV (~\$900-\$9,800 /cycle)	~\$1,000-\$9,900/cycle	(Part B); generic decitabine per formulary; Inqovi (oral decitabine/cedazuridine) is brand-only (~\$9,000/cycle) = oral convenience but no generic savings
Onureg (oral azacitidine) 300 mg days 1-14 (~\$25,400/cycle)	No generic available	N/A	(Part D); maintenance indication only (not interchangeable with injectable azacitidine); significantly higher cost than injectable generic azacitidine
Xospata (gilteritinib) 120 mg/day (~\$18,000-\$22,000/mo)	No generic available	N/A	(Part D); FLT3-mutated R/R AML only : confirm mutation status before initiating; patient assistance program available; total monthly costs lower than intensive chemo (\$47,218 vs. \$171,982 all-cause)

BRAND (EST. COST) ⁴⁹⁻⁵¹	GENERIC/ ALTERNATIVE (EST. COST) ^{49,52}	EST. MONTHLY SAVINGS	COST-SMART TIP (MEDICARE COVERAGE) ^{5,53,54}
Tibsovo (ivosidenib) 500 mg/day (~\$28,000- \$32,000 /mo)	No generic available	N/A	(Part D); IDH1-mutated AML only ; ICER ~\$253,000/QALY vs. azacitidine alone, cost-effectiveness debated; patient assistance program essential for most patients
Blincyto (blinatumomab) (~\$89,000- \$178,000/cycle depending on indication)	No generic available	N/A	(Part B; infusion); requires continuous IV infusion pump = significant nursing/ pharmacy coordination; increasingly used in frontline ALL consolidation; patient assistance available
Besponsa (inotuzumab ozogamicin) 1.8 mg/m²/cycle (~\$42,000-\$56,000/ cycle)	No generic available	N/A	(Part B); R/R CD22+ B-ALL; monitor LFTs closely (SOS/VOD risk, especially pre-HCT); limit to ≤6 cycles per label
Generic 6-MP + methotrexate (ALL maintenance) (~\$50-\$200/mo)	Already generic	N/A	Lowest-cost phase of ALL treatment; PCP role: monitor CBC, LFTs; reinforce adherence; thiopurine methyltransferase (TPMT) testing should be on file

ABBREVIATIONS: AML = acute myeloid leukemia; ALL = acute lymphoblastic leukemia; CBC = complete blood count; FLT3 = FMS-like tyrosine kinase 3; HCT = hematopoietic cell transplantation; HMA = hypomethylating agent; ICER = incremental cost-effectiveness ratio; IDH1 = isocitrate dehydrogenase 1; IV = intravenous; LFTs = liver function tests; mo = month; QALY = quality-adjusted life-year; R/R = relapsed/refractory; SC = subcutaneous; SOS/VOD = sinusoidal obstruction syndrome/veno-occlusive disease; TPMT = thiopurine methyltransferase; 6-MP = 6-mercaptopurine

Patient Education and Adherence



AAVBC PERSPECTIVE

Acute leukemia treatment decisions carry profound implications for quality of life, and they must be made **with patients, not for them**. For older adults, the choice between intensive induction chemotherapy, outpatient HMA + venetoclax, or best supportive care is shaped by functional status (**biological age** rather than chronological age), comorbidities, personal goals, and caregiver support. Shared decision-making conversations should cover **realistic expected outcomes (VIALE-A: median OS 14.7 months with azacitidine + venetoclax vs. 9.6 months with azacitidine alone; historically ~5-6 months with low-dose cytarabine and ~2-3 months with best supportive care in unfit older adults)**,^{45,55} **daily treatment burden**,

infection risk during neutropenia, and advance care planning. These conversations generate **documentable clinical work**: advance care planning (**CPT 99497/99498; MIPS #047**) with surrogate designation and code status, geriatric assessment findings (**G8, SPPB**) that inform treatment intensity, caregiver and social support evaluation for outpatient regimen feasibility, and explicit shared decision-making narrative when patients choose or decline intensive therapy. PCPs hold the relational context oncology teams often lack: documenting the patient's expressed values, goals, and support system turns a treatment plan into a **patient-led care trajectory**.

Patients should know the warning signs warranting **urgent evaluation**: fever $\geq 38.0^{\circ}\text{C}$ (call oncology immediately, **do not wait**); new bleeding, bruising, or petechiae (possible worsening thrombocytopenia); **new shortness of breath** or **rapid weight gain** (possible differentiation syndrome or tumor lysis syndrome → same-day contact); and **signs of infection** such as chills, sore throat, or dysuria during neutropenic periods. Venetoclax adherence is foundational: take at the same time daily with a meal, strictly avoid grapefruit juice, and inform all clinicians and pharmacists of the regimen **before** any new prescription is dispensed to prevent CYP3A4 interactions.

Quality Metrics Tie-In

Acute leukemia intersects **multiple quality measurement domains**: oncology-specific end-of-life metrics (NQF #0210, #0213, #0215/0216), geriatric care (COA, advance care planning), care transitions (medication reconciliation, readmissions), and depression screening. The disease's high early mortality, prolonged cytopenias with frequent ED utilization, complex polypharmacy (particularly CYP3A4-mediated venetoclax interactions), and rapid functional decline in older adults mean that nearly every major HEDIS, MIPS, and CMS value-based program measure applies simultaneously across the care trajectory.

MEASURE	STANDARD	NOTES
HEDIS: Care for Older Adults (COA) - Medication Review	Denominator : MA enrollees ≥ 66 , continuously enrolled; Numerator : 4 sub-measures documented annually: (1) functional status assessment, (2) medication review, (3) pain assessment, (4) advance care planning; Exclusions : hospice, ESRD	Most directly applicable cross-cutting measure for elderly leukemia patients; SPPB, G8, and medication reconciliation for venetoclax interactions satisfy multiple sub-measures simultaneously
HEDIS: Medication Reconciliation Post-Discharge (MRP)	Denominator : enrollees ≥ 18 discharged from inpatient facility; Numerator : medication reconciliation completed within 30 days of discharge; Exclusions : hospice	Critical for AML patients post-induction hospitalization; CYP3A4 screening for venetoclax, azole antifungal dose adjustments, and polypharmacy review at every transition

MEASURE	STANDARD	NOTES
HEDIS: Plan All-Cause Readmissions (PCR)	Denominator: acute inpatient discharges for enrollees ≥ 18 , discharged alive; Numerator: unplanned readmission within 30 days; Exclusions: planned readmissions, transfers, AMA discharges, cancer medical treatment admissions	AML induction carries high readmission rates for febrile neutropenia, bleeding, and infection; cancer treatment admissions excluded from denominator
MIPS #047: Advance Care Planning	Denominator: patients ≥ 65 with ≥ 1 qualifying encounter during reporting period; Numerator: advance care plan or surrogate decision-maker documented, OR documentation that ACP was discussed but patient declined; Exclusions: none specified	Billable as CPT 99497/99498 during AWW with no patient copay; particularly high-value in acute leukemia given treatment intensity decisions and prognosis discussions
MIPS #134: Depression Screening (PHQ-9)	Denominator: patients ≥ 12 with ≥ 1 qualifying encounter; Numerator: screened for depression using PHQ-9 AND follow-up plan documented if positive; Exclusions: active depression diagnosis with current treatment	NCCN recommends distress screening at every visit for all cancer patients; ⁴⁰ acute leukemia patients face high psychosocial burden from prolonged hospitalization, functional decline, and uncertain prognosis
NQF #0210: Chemotherapy in Last 14 Days of Life	Denominator: patients who died of cancer during measurement period; Numerator: patients who received systemic therapy (including targeted agents) in last 14 days of life; Lower is better	Applies to venetoclax, HMA, and all systemic agents; early palliative care integration and goals-of-care documentation reduce rates
NQF #0213: ICU Admission in Last 30 Days of Life	Denominator: patients who died of cancer; Numerator: #0215 = not referred to hospice; #0216 = hospice referral ≤ 3 days before death. Lower is better	EOM quality score includes hospice enrollment ≥ 3 days before death; document hospice eligibility assessment at each visit when prognosis is limited
CMS OP-35: Chemo-Associated ED/Hospitalization (30-day)	Denominator: 6-month chemotherapy episodes; Numerator: episodes with ≥ 1 chemotherapy-associated ED visit or hospitalization within 30 days of treatment; Lower is better	Document chemo date, ANC nadir, fever management, reason for any ED contact; included in EOM performance scoring

ABBREVIATIONS: HEDIS = Healthcare Effectiveness Data and Information Set; COA = Care for Older Adults; MA = Medicare Advantage; ESRD = end-stage renal disease; SPPB = Short Physical Performance Battery; MRP = Medication Reconciliation Post-Discharge; CYP3A4 = cytochrome P450 3A4; AML = acute myeloid leukemia; PCR = Plan All-Cause Readmissions; AMA = against medical advice; MIPS = Merit-based Incentive Payment System; ACP = advance care planning; CPT = Current Procedural Terminology; AWW = annual wellness visit; NQF = National Quality Forum; HMA = hypomethylating agent; ICU = intensive care unit; EOM = Enhancing Oncology Model; PHQ-9 = Patient Health Questionnaire—9; NCCN = National Comprehensive Cancer Network; CMS = Centers for Medicare & Medicaid Services; ED = emergency department; ANC = absolute neutrophil count



QUALITY OUTCOME

When primary care maintains accurate leukemia subtype coding, documents geriatric assessment findings that inform treatment intensity decisions, coordinates CYP3A4 drug interaction screening at every visit, and integrates palliative care concurrently rather than at end of life, patients experience **fewer chemotherapy-associated ED visits, lower readmission rates** during neutropenic periods, and **improved continuity** across oncology and primary care. Quality outcomes follow naturally from delivering and documenting the care the clinical picture demands: **Stars, MIPS, and EOM scores** are consequences of good care, not separate goals.



DOCUMENTATION: GOOD DOCUMENTATION IS COMPREHENSIVE CODING

When a treatment decision is reached between oncology and the patient, the PCP note should confirm:

- (1) Specific cell-type code with 6th-character status (e.g., **C92.01** AML in remission vs. **C91.00** ALL not having achieved remission)
- (2) Current treatment phase (active induction/consolidation/maintenance/surveillance/best supportive care)
- (3) Most recent CBC with date and values,
- (4) Functional status with trend (SPPB, G8)
- (5) Advance care plan status

This anchors subsequent care in a **transparent clinical record** rather than fragmented specialist notes and ensures MEAT documentation is satisfied **at every encounter**.

5 CODING REMINDERS AND CASE EXAMPLES

Documentation Specificity

- **Stage/Severity:** Specify AML vs. ALL lineage, then ELN 2022 risk category for AML (**favorable/intermediate/adverse**)²⁷ or Ph-status for ALL; this sub-classification drives **HCC mapping** and **treatment eligibility**^{14,15,36}
- **Etiology:** Document prior MDS/MPN, prior cytotoxic therapy, occupational benzene/ petrochemical exposure, or genetic syndromes (Down, Fanconi): secondary vs. de novo status affects **prognosis** and **regimen choice**
- **Current status:** Most recent CBC with date (ANC, Hgb, platelets), current cycle/phase of treatment, and functional measure (SPPB or ECOG); update every encounter during the reporting year

- **Associated conditions:** Febrile neutropenia (**D70.1 + R50.81**), DIC (**D65**), TLS (**E88.3**), chemotherapy-induced anemia (**D64.81**); each carries independent clinical and coding significance
- **Chronicity:** Diagnosis date, cycle number, duration in remission; distinguishes active surveillance (**C91.01/C92.01**) from Z85.6 (applies **ONLY** when all active therapy is complete)

Annual Clinical Review and Confirmation

- **Annual review:** AML and ALL must be reassessed face-to-face or via synchronous audio-video telehealth **each reporting year** = update cell type, ELN risk category, and 6th-character remission status
- **Visit modality:** In-person or video telehealth with meaningful evaluation qualifies; document functional assessment and laboratory review.
- **Clinical context:** Under HCC V28, accurate cell-type and staging mapping matters: **HCC 17** (AML) at RAF ~4.209 differs meaningfully from **HCC 18** (ALL/unspecified) at 2.341; the goal is accurate clinical complexity representation, not code optimization
- **Avoid rollover: Do not** copy last year's AML note forward without updating CBC with date, current cycle/phase, functional status, and patient-reported goals of care

Good Documentation is Comprehensive Coding

EHR SHORTCUT/RISK	PREFERRED DOCUMENTATION LANGUAGE ^{14,15}
'Leukemia' on problem list	'AML (C92.01), ELN 2022 intermediate risk, in complete remission on maintenance azacitidine + venetoclax, last oncology visit [date]'
'History of leukemia' in an actively monitored patient	'AML in remission (C92.01) — on active maintenance therapy; annual MEAT required. Do not use Z85.6 until all active therapy has ended.'
Copy-forward 'AML' from last year without re-confirmation	'AML (C92.01), reconfirmed today: CBC from [date] (ANC, Hgb, platelets), current regimen [name], patient goals unchanged. Annual clinical review complete.'
'Chemo-induced anemia'	'Anemia due to antineoplastic chemotherapy (D64.81) from maintenance azacitidine + venetoclax for AML (C92.01): transfusion-dependent, last transfusion [date].'
'Febrile neutropenia'	'Febrile neutropenia — T 38.6°C, ANC 320/μL, on maintenance venetoclax for AML (C92.01); blood cultures drawn; empiric cefepime initiated.'; codes: D70.1 + R50.81 + C92.01

EHR SHORTCUT/RISK	PREFERRED DOCUMENTATION LANGUAGE ^{14,15}
'Unspecified acute leukemia' after pathology has returned	'Acute myeloid leukemia, ELN [risk], active, not in remission (C92.00)'; update once pathology is confirmed; C95.0x should not persist once lineage is known
ABBREVIATIONS: AML = acute myeloid leukemia; ANC = absolute neutrophil count; CBC = complete blood count; CMP = comprehensive metabolic panel; ELN = European LeukemiaNet; MEAT = monitor/evaluate/assess/treat; SPPB = Short Physical Performance Battery	

EHR Workflow Tips

[EHR TIP — Smartphrase] Build a **.alvisit dot phrase** that auto-populates ICD-10 with 6th character status, cell type and ELN risk category, most recent CBC with differential (with date), current regimen/cycle/day, SPPB score with trend, advance care plan status, and a medication reconciliation flag that screens for CYP3A4 interactions — sourced from oncology notes, lab results, and pharmacy records. Reduces unspecified leukemia coding and supports MEAT documentation in a single paste.

[EHR TIP — Alert] Worklist filter "**Acute Leukemia Active**" = surfaces patients with C91.xx, C92.xx, or C95.0x (6th character = 0 or 1) or any patient with a Z51.11 antineoplastic chemotherapy encounter in the last 12 months plus leukemia on the problem list. Identifies active patients due for PCP-level follow-up or lab review.

[EHR TIP — Best Practice] Problem list hygiene: maintain the problem list entry as specific (e.g., "AML, ELN 2022 intermediate risk, in complete remission"), **not** "leukemia." Update the 6th character **at every reassessment**; never leave as "unspecified" after pathology confirmation. Code each active comorbidity **individually** (pancytopenia D61.810, cardiotoxicity monitoring I25.x, secondary infection history).

[EHR TIP — Workflow] Annual diagnosis confirmation: fire a BPA when an active leukemia code (C91.xx, C92.xx, C94.xx, C95.0x) appears on the problem list and no face-to-face or synchronous audio-video encounter with MEAT documentation has been recorded in the past 12 months. Fires at year-end to support HCC mapping and RAF continuity before the sweep deadline.

[EHR TIP — Order Set] "**Acute Leukemia Surveillance Labs**" order set: CBC with differential, CMP, LDH, uric acid, peripheral smear review; frequency adjustable per treatment phase (induction/consolidation/maintenance/surveillance). New-diagnosis add-on bundle includes hematology/oncology referral, palliative care consult, and genetic counseling referral = all triggered at problem list entry.

[EHR TIP — Auto-prompt] Triggered **referral cascade** at new acute leukemia diagnosis: hematology/oncology, cardio-oncology (anthracycline-eligible patients), palliative care (concurrent, not end-of-life only), and genetic counseling. **During active treatment:** G-8 ≤ 14 fires a geriatric oncology referral prompt; SPPB < 9 fires a physical therapy referral prompt. One-click referral template auto-populates reason for referral and most recent labs.

Brief Case Examples

SUCCESS: COMPREHENSIVE DOCUMENTATION

SCENARIO

A 72-year-old female patient with AML diagnosed 9 months ago, ELN 2022 **intermediate risk**, on maintenance azacitidine + venetoclax after lower-intensity induction. Presents to PCP for routine follow-up; reports fatigue but no fever, no new bleeding. PCP reviewed most recent oncology CBC, performed functional assessment, and documented the full clinical picture in a single encounter:

Documentation: "Acute myeloid leukemia (**C92.01**), ELN 2022 intermediate risk, in complete remission on maintenance azacitidine 75 mg/m² days 1-7 + venetoclax 400 mg daily (cycle 10), last oncology visit [date] with Dr. [Name]. Reviewed CBC from [date]: ANC 1,200/μL, Hgb 10.2 g/dL, platelets 92,000/μL. SPPB today = 7 (declined from 9 three months ago). No fever, no new bleeding. Advance care plan on file, patient confirms unchanged goals. Assessment: AML in remission = continue current oncology regimen; physical therapy referred for functional decline. Chemotherapy-induced pancytopenia (**D61.810**). Return 6 weeks or sooner if fever ≥38.0°C or new bleeding."

Outcome: HCC 17 (active malignancy) confirmed with specific cell type and remission status; chemotherapy-induced pancytopenia documented as a distinct coded comorbidity; functional decline captured with SPPB trend supporting geriatric reassessment; advance care plan documented per **MIPS #047**. Every MEAT element present: regimen with dose and cycle number, CBC with date and values, functional measure with trend, coded diagnoses, treatment plan with follow-up interval and symptom-based return criteria.

PITFALL: INSUFFICIENT DOCUMENTATION

Documentation as written: "Hx of leukemia, stable. CBC ok. Continue current meds. F/u 3 months." **Coded as Z85.6** (personal history of leukemia). The chart does not specify cell type (AML vs. ALL), remission status, regimen name, CBC values or date, functional status, or advance care plan.

Consequence: "Hx of" on an active-maintenance patient triggers Z85.6 = **eliminates HCC mapping entirely**. No 6th-character remission status, no regimen documentation, and "CBC ok" without values or date **fails** MEAT on every element. The record understates the clinical complexity the team is actually managing and impairs continuity between PCP and oncology.

RAF Impact: Z85.6 carries zero HCC value. With proper documentation (**C91.01** or **C92.01** with remission status + coded comorbidities), the record reflects the substantive ongoing work the care team is doing.

Fix: Update problem list and assessment: "ALL (**C91.01**) in complete molecular remission; 3.5 years post-initial induction, on maintenance 6-MP + methotrexate per hematology (Dr. [Name], last seen [date]). Reviewed CBC from [date]: WBC 4.2, Hgb 12.8, platelets 165,000. SPPB 10, gait steady. No B symptoms, no bleeding. Advance care plan reviewed, no changes. Continue the current regimen. Return 3 months; sooner for fever ≥38.0°C, new bleeding, or unexplained fatigue." Coding after fix: **C91.01** (ALL in remission → **HCC 18**) + **Z79.899** (long-term drug therapy) = real clinical picture preserved.

REFERENCES

1. Venugopal S, Sekeres MA. Contemporary Management of Acute Myeloid Leukemia: A Review. *JAMA Oncol.* 2024;10(10):1417-1425. doi:10.1001/jamaoncol.2024.2662
2. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. *CA Cancer J Clin.* 2025;75(1):10-45. doi:10.3322/caac.21871

- 3.DiNardo CD, Erba HP, Freeman SD, Wei AH. Acute myeloid leukaemia. *Lancet Lond Engl*. 2023;401(10393):2073-2086. doi:10.1016/S0140-6736(23)00108-3
- 4.Sasaki K, Jabbour E, Short NJ, et al. Acute lymphoblastic leukemia: A population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980–2017. *Am J Hematol*. 2021;96(6):650-658. doi:10.1002/ajh.26156
- 5.Brunner AM, Huggar D, Copher R, et al. Economic burden during remission and after relapse among older patients with newly diagnosed acute myeloid leukemia without hematopoietic stem cell transplant: A retrospective study using the SEER-Medicare database. *Leuk Res*. 2023;132:107353. doi:10.1016/j.leukres.2023.107353
- 6.Muffly L, Young C, Feng Q, Nimke D, Pandya BJ. Healthcare resource utilization and costs during first salvage therapy for relapsed or refractory acute myeloid leukemia in the United States. *Leuk Lymphoma*. 2023;64(11):1832-1839. doi:10.1080/10428194.2023.2235044
- 7.Barlev A, Lin VW, Song X. Burden of hospitalization in relapsed acute lymphoblastic leukemia. *Curr Med Res Opin*. 2016;32(7):1209-1212. doi:10.1185/03007995.2016.1164677
- 8.Bonafede M, Anaissie E, Evans K, Itzler R. Healthcare utilization and cost of cancer-related care prior to allogeneic hematopoietic cell transplantation for hematologic malignancies in the US: a retrospective real-world analysis. *BMC Health Serv Res*. 2021;21(1):1125. doi:10.1186/s12913-021-07150-4
- 9.Centers for Medicare & Medicaid Services (CMS), National Center for Health Statistics (NCHS), American Hospital Association (AHA), American Health Information Management Association (AHIMA). *ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026*. U.S. Department of Health and Human Services; 2025. <https://www.cms.gov/medicare/coding-billing/icd-10-codes>
- 10.Centers for Medicare & Medicaid Services. *2026 Final ICD-10-CM Mappings (CMS-HCC V28)*. U.S. Department of Health and Human Services; 2025. <https://www.cms.gov/medicare/health-plans/medicareadvtspecratestats/risk-adjustors/2026-model-software>
- 11.Centers for Medicare & Medicaid Services. *CMS-HCC Model Relative Factor Tables (Community, Non-Dual, Aged)*. 2024. <https://www.cms.gov/files/document/revised-cms-hcc-model-relative-factor-tablespdf>
- 12.de Haas V, Ismaila N, Advani A, et al. Initial diagnostic work-up of acute leukemia: ASCO clinical practice guideline endorsement of the College of American Pathologists and American Society of Hematology guideline. *J Clin Oncol*. 2019;37(3):239-253. doi:10.1200/JCO.18.01468
- 13.Arber DA, Borowitz MJ, Cessna M, et al. Initial diagnostic workup of acute leukemia: guideline from the College of American Pathologists and the American Society of Hematology. *Arch Pathol Lab Med*. 2017;141(10):1342-1393. doi:10.5858/arpa.2016-0504-CP
- 14.National Comprehensive Cancer Network. *NCCN Clinical Practice Guidelines in Oncology: Acute Lymphoblastic Leukemia*. Version 1.2026. National Comprehensive Cancer Network; 2026. <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1413>
- 15.National Comprehensive Cancer Network. *NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia*. Version 3.2026. National Comprehensive Cancer Network; 2025. <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1411>
- 16.Murphy JD, Russell NG, Busch DW. Relapsed AML in a Patient Presenting to a College Health Center: A Case Report. *J Pediatr Health Care*. 2025;39(3):453-458. doi:10.1016/j.pedhc.2024.10.006

17. Kantarjian H, Aldoss I, Jabbour E. Management of Adult Acute Lymphoblastic Leukemia: A Review. *JAMA Oncol.* 2025;11(7):771-778. doi:10.1001/jamaoncol.2025.0613
18. National Comprehensive Cancer Network. *NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes*. Version 3.2026. National Comprehensive Cancer Network; 2026. <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1427>
19. Alteri R, Baptiste D, Bell EB. *Cancer Prevention Early Detection Facts Figures 2025-2026*. American Cancer Society; 2025. Accessed April 24, 2026. <https://www.cancer.org/research/acs-cancer-facts-figures/cancer-prevention-early-detection-facts-figures.html>
20. Sekeres MA, Taylor J. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review. *JAMA.* 2022;328(9):872-880. doi:10.1001/jama.2022.14578
21. Rhee JW, Bolton KL, Gupta D, et al. Clonal Hematopoiesis and Its Cardiovascular Implications: A Scientific Statement From the American Heart Association. *Circulation.* 2026;153(11):e940-e952. doi:10.1161/CIR.0000000000001404
22. Linet MS, Gilbert ES, Vermeulen R, et al. Benzene Exposure Response and Risk of Myeloid Neoplasms in Chinese Workers: A Multicenter Case-Cohort Study. *J Natl Cancer Inst.* 2019;111(5):465-474. doi:10.1093/jnci/djy143
23. Verma A, Lupo PJ, Shah NN, Hitzler J, Rabin KR. Management of Down Syndrome-Associated Leukemias: A Review. *JAMA Oncol.* 2023;9(9):1283-1290. doi:10.1001/jamaoncol.2023.2163
24. Savage SA, Dufour C. Classical inherited bone marrow failure syndromes with high risk for myelodysplastic syndrome and acute myelogenous leukemia. *Semin Hematol.* 2017;54(2):105-114. doi:10.1053/j.seminhematol.2017.04.004
25. Gbenjo JTC, McCrary GLM, Wilson SE. Leukemia: What Primary Care Physicians Need to Know. *Am Fam Physician.* 2023;107(4):397-405.
26. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. *Leukemia.* 2022;36(7):1703-1719. doi:10.1038/s41375-022-01613-1
27. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. *Blood.* 2022;140(12):1345-1377. doi:10.1182/blood.2022016867
28. Thalhammer-Scherrer R, Mitterbauer G, Simonitsch I, et al. The immunophenotype of 325 adult acute leukemias: relationship to morphologic and molecular classification and proposal for a minimal screening program highly predictive for lineage discrimination. *Am J Clin Pathol.* 2002;117(3):380-389. doi:10.1309/C38D-D8J3-JU3E-V6EE
29. National Comprehensive Cancer Network. *NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia*. Version 1.2026. National Comprehensive Cancer Network; 2025. https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf
30. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. *Am J Hematol.* 2024;99(11):2191-2212. doi:10.1002/ajh.27443
31. National Comprehensive Cancer Network. *NCCN Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma*. Version 2.2026. National Comprehensive Cancer Network; 2025. https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf

32. Wu D, Li W, Luo L, Ding F. Acute myeloid leukemia presenting with gingival enlargement masked by a normal complete blood count: A case of delayed diagnosis and literature review. *Medicine (Baltimore)*. 2025;104(51):e46684. doi:10.1097/MD.00000000000046684
33. O'Brien J, Tomlinson B, Patel MJ, et al. ATRA treatment in the emergency department is associated with reduced early mortality in acute promyelocytic leukemia-a real-world multicenter retrospective cohort analysis. *Leuk Lymphoma*. 2026;67(5):1005-1013. doi:10.1080/10428194.2026.2623196
34. Macaron W, Sargsyan Z, Short NJ. Hyperleukocytosis and leukostasis in acute and chronic leukemias. *Leuk Lymphoma*. 2022;63(8):1780-1791. doi:10.1080/10428194.2022.2056178
35. Kantarjian H, Jabbour E. Adult Acute Lymphoblastic Leukemia: 2025 Update on Diagnosis, Therapy, and Monitoring. *Am J Hematol*. 2025;100(7):1205-1231. doi:10.1002/ajh.27708
36. Sekeres MA, Mattison R, Artz A, et al. American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. *Blood Adv*. 2026;10(6):1897-1928. doi:10.1182/bloodadvances.2025017934
37. National Comprehensive Cancer Network. *NCCN Clinical Practice Guidelines in Oncology: Hematopoietic Growth Factors*. Version 3.2026. National Comprehensive Cancer Network; 2025.
38. National Comprehensive Cancer Network. *NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma*. Version 5.2026. National Comprehensive Cancer Network; 2026.
39. Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. *Lancet Lond Engl*. 2013;381(9865):484-495. doi:10.1016/S0140-6736(12)61727-9
40. National Comprehensive Cancer Network. *NCCN Clinical Practice Guidelines in Oncology: Older Adult Oncology*. 2025. https://www.nccn.org/professionals/physician_gls/pdf/senior.pdf*
41. Min GJ, Cho BS, Park SS, et al. Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AML. *Blood*. 2022;139(11):1646-1658. doi:10.1182/blood.2021013671
42. Kwag D, Cho BS, Park S, Kim HJ. Objectively measured physical function predicts mortality in older adults with acute myeloid leukemia treated by lower-intensity therapy: A prospective cohort study. *J Geriatr Oncol*. 2025;16(8):102335. doi:10.1016/j.jgo.2025.102335
43. Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. *Blood*. 2022;140(11):1200-1228. doi:10.1182/blood.2022015850
44. Shimony S, Stahl M, Stone RM. Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management. *Am J Hematol*. 2025;100(5):860-891. doi:10.1002/ajh.27625
45. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. *N Engl J Med*. 2020;383(7):617-629. doi:10.1056/NEJMoa2012971
46. Bhatt VR, Wichman CS, Koll TT, et al. A Phase II Trial of Geriatric Assessment-Guided Selection of Treatment Intensity in Older Adults With AML. *Am J Hematol*. 2025;100(7):1163-1172. doi:10.1002/ajh.27694
47. Scheepers ERM, Vondeling AM, Thielen N, van der Griend R, Stauder R, Hamaker ME. Geriatric assessment in older patients with a hematologic malignancy: a systematic review. *Haematologica*. 2020;105(6):1484-1493. doi:10.3324/haematol.2019.245803

48. Krüger K, Gabdoulline R, Wichmann M, et al. Prognostic Role of Kidney Disease in Newly Diagnosed Acute Myeloid Leukemia Under Venetoclax-Based Low-Intensity Therapy. *Cancers*. 2025;17(18). doi: 10.3390/cancers17182993
49. Short NJ, Kantarjian H. Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions. *Am J Hematol*. 2022;97(12): 1616-1626. doi:10.1002/ajh.26667
50. Pratz KW, Chai X, Xie J, et al. Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective. *PharmacoEconomics*. 2022;40(8):777-790. doi:10.1007/s40273-022-01145-7
51. Delea TE, Zhang X, Amdahl J, et al. Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States. *PharmacoEconomics*. 2019;37(9):1177-1193. doi:10.1007/s40273-019-00812-6
52. U.S. Food and Drug Administration. *Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)*. 46th ed. U.S. Food and Drug Administration; 2026. <https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book>
53. Bewersdorf JP, Patel KK, Goshua G, et al. Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia. *Leuk Lymphoma*. 2023;64(2):454-461. doi:10.1080/10428194.2022.2140288
54. Bewersdorf JP, Huntington SF, Zeidan AM. Cost-Effectiveness Analyses in AML: What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future? *J Natl Compr Cancer Netw JNCCN*. 2023;21(5):522-528. doi:10.6004/jnccn.2023.70012
55. Pratz KW, Jonas BA, Pullarkat V, et al. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. *Am J Hematol*. 2024;99(4):615-624. doi: 10.1002/ajh.27246

Medical Disclaimer

The information provided by the American Academy of Value-Based Care (AAVBC) in this document, including but not limited to coding guidance, and related content, is intended for educational and informational purposes only. This content is designed to assist healthcare providers, organizations, and professionals in understanding and applying Value-Based Care principles, practices, and regulatory compliance standards.

AAVBC does not provide legal, clinical, or medical advice. The content presented should not be interpreted or relied upon as specific legal, medical, clinical, or professional guidance. While efforts are made to ensure the accuracy and currency of the information provided, AAVBC does not guarantee that the materials presented are complete, comprehensive, or without error.

Providers and healthcare professionals must independently evaluate all content and guidance presented herein in the context of applicable laws, regulations, clinical guidelines, payer policies, patient-specific conditions, and contraindications. Any treatments, procedures, diagnostic approaches, medications, or strategies discussed are illustrative and should not be directly applied without a thorough and independent review of current, evidence-based clinical resources, and regulatory requirements.

For coding, documentation, utilization management, quality measures (including STAR ratings), and compliance matters, users are responsible for consulting official guidelines issued by regulatory bodies, including but not limited to the Centers for Medicare and Medicaid Services (CMS), the American Medical Association (AMA), relevant state agencies, and other authoritative entities.

AAVBC expressly disclaims liability for any loss, claim, or damages arising directly or indirectly from the use or reliance on information provided in this document. Users should consult their organization's legal counsel, compliance officer, or qualified professional advisor for advice specific to their situation. By accessing and using this document, you agree to AAVBC's terms and acknowledge that the use of the content is at your own risk and discretion.